688639 华恒生物
2025/09 - 九个月2024/122023/122022/122021/12

盈利能力分析
净资产收益率 ROE (%)6.3898.63127.15424.03020.113
总资产报酬率 ROA (%)3.1454.23114.97518.28115.177
投入资产回报率 ROIC (%)3.6575.13118.74422.26718.626

边际利润分析
销售毛利率 (%)23.55024.92440.51638.65932.330
营业利润率 (%)7.9539.15226.35924.11119.531
息税前利润/营业总收入 (%)9.10710.28526.28023.70319.975
净利润/营业总收入 (%)7.2688.47423.04122.51017.633

收益指标分析
经营活动净收益/利润总额(%)100.02079.90396.89795.15488.745
价值变动净收益/利润总额(%)-0.9440.4240.5032.1833.431
营业外收支净额/利润总额(%)-1.8231.037-0.9150.2742.329

偿债能力分析
流动比率 (X)1.4450.8430.6262.2204.661
速动比率 (X)1.0050.5890.4911.8714.080
资产负债率 (%)52.96448.72454.01626.90819.740
带息债务/全部投入资本 (%)41.41334.88036.982-0.233-4.042
股东权益/带息债务 (%)131.178173.836156.433-38,972.633-2,358.525
股东权益/负债合计 (%)89.288105.49785.190271.431406.598
利息保障倍数 (X)7.0249.913164.477-50.050-919.204

营运能力分析
应收账款周转天数 (天)33.95443.76747.00355.34349.860
存货周转天数 (天)73.29969.72656.51250.00042.743